Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study.
Journal of Hepatology(2019)
Abstract
•In patients with chronic HBV infection, T cell responses are inhibited, leading to an inability to control the virus.•One of the most common inhibitors present on exhausted T cells is PD-1, which likely contributes to T cell dysfunction.•A single dose of either 0.1 or 0.3 mg/kg of nivolumab, with or without GS-4774, was well tolerated and effective.
MoreTranslated text
Key words
Chronic hepatitis B,GS-4774,Nivolumab,Receptor occupancy,T cell response,HBV,Immune-checkpoint inhibitors,Immunology
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined